This paper reports the results of an international survey on research data management (RDM) services in libraries. More than 240 practicing librarians responded to the survey and outlined their roles and levels of preparedness in providing RDM services, challenges their libraries face, and knowledge and skills that they deemed essential to advance the RDM practice. Findings of the study revealed not only a number of location and organizational differences in RDM services and tools provided but also the impact of the level of preparedness and degree of development in RDM roles on the types of RDM services provided. Respondents’ perceptions on both the current challenges and future roles of RDM services were also examined. With a majority of the respondents recognizing the importance of RDM and hoping to receive more training while expressing concerns of lack of bandwidth or capacity in this area, it is clear that, in order to grow RDM services, institutional commitment to resources and training opportunities is crucial. As an emergent profession, data librarians need to be nurtured, mentored, and further trained. The study makes a case for developing a global community of practice where data librarians work together, exchange information, help one another grow, and strive to advance RDM practice around the world.
Zhu Chen, Yi-lan Zeng, Li Wang, Rong Hu, Yan Wang, Yu-zhen Tang, Li Zhu and Bei Wu
Objective To compare the efficacy of peginterferon alfa-2a (PEGASYS) plus ribavirin (RBV) with interferon alfa-2a plus RBV, and evaluate the safety.
Methods Total of 117 patients with chronic hepatitis C were enrolled to receive either PEGASYS (135 μg or 180 μg) subcutaneously once per week, plus RBV (800 mg-1 200 mg) per day for 48 weeks (79 patients, PEGASYS group), or 5 million units of interferon alfa-2a subcutaneously every other day, plus RBV as above dosage for 48 weeks (38 patients, IFNα group).
Results Sixty-three of 79 (79.7%) patients reached sustained virological response (SVR) in PEGASYS group, while 14 of 38 (36.8%) patients reached SVR in IFNα group. PEGASYS group was associated with a higher rate of virologic response than IFNα group at week 4, 12, 36, 48 and week 72. Sustained normalization of serum ALT concentrations at week 36, 48 and week 72 was also more common in PEGASYS group than in IFNα group. Baseline levels of ALT and HCV RNA had no effect on SVR in either PEGASYS group or IFNα group. Both groups were similar in the frequency and severity of adverse events.
Conclusions PEGASYS plus RBV produced similar adverse events but higher rate of SVR. Meanwhile, complications should be prevented and treated promptly in order to increase compliances and effects.